<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835741</url>
  </required_header>
  <id_info>
    <org_study_id>21641</org_study_id>
    <nct_id>NCT03835741</nct_id>
  </id_info>
  <brief_title>Automated Adjustment of Oxygen on Patient With Acute COPD Exacerbation - FreeO2 HypHop</brief_title>
  <acronym>FreeO2 HypHop</acronym>
  <official_title>Reduction of Length of Stay by Automated Adjustment of Oxygen on Patient With Acute COPD Exacerbation - FreeO2 HypHop</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if automated adjustment of oxygen (with FreeO2 device)
      can reduce the hospital length of stay for acute exacerbation of COPD with comparison of
      manual oxygen titration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate if automated adjustment of oxygen (with FreeO2 device)
      can reduce the hospital length of stay for acute exacerbation of COPD with comparison of
      manual oxygen titration.

      Patients with severe acute exacerbation of COPD requiring hospitalization will be included in
      this randomized controlled study and will be managed with either manual oxygen titration or
      automated oxygen titration (FreeO2 arm).

      The impact on the hospital length of stay will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>From hospital admission until hospital discharge (around one week expected)</time_frame>
    <description>Duration of the hospital length of stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU transfer</measure>
    <time_frame>During hospital stay : from hospital admission until hospital discharge (around one week expected)</time_frame>
    <description>The rate of ICU admission during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen administration duration</measure>
    <time_frame>During hospital stay : from hospital admission until hospital discharge (around one week expected)</time_frame>
    <description>The number of days patient receive oxygen supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non invasive or invasive mechanic ventilation rate use</measure>
    <time_frame>During hospital stay: from hospital admission until hospital discharge (around one week expected)</time_frame>
    <description>The rate of NIV use during length of stay in hospital</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Arterial or Capillary blood gaz evolution</measure>
    <time_frame>During hospital stay - From hospital admission until hospital discharge (around one week expected)</time_frame>
    <description>Evaluation of the rate of respiratory acidosis (pH&lt;7.35 and PaCO2&gt;45mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Readmission rate after hospital discharge</measure>
    <time_frame>Until day 90 after study inclusion</time_frame>
    <description>Rate of hospital readmission after initial hospital discharge</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Oxygen Toxicity</condition>
  <condition>COPD Exacerbation</condition>
  <condition>Hyperoxia</condition>
  <condition>Hypoxemia</condition>
  <condition>Hypoxic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Automated Oxygen titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual Oxygen titration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeO2</intervention_name>
    <description>an automated adjustment of oxygen during patient hospitalisation by FreeO2 device</description>
    <arm_group_label>Automated Oxygen titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>manual titration</intervention_name>
    <description>a manual adjustment of oxygen during patient hospitalisation by hospital staff</description>
    <arm_group_label>Manual Oxygen titration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD or suspected COPD ( Age&gt;40, active or smoking history &gt; 10pack/years), -

          -  Acute exacerbation (increasing dyspnea recently)

          -  One or more of the following criteria: increased sputum, modification of sputum
             purulence,increased dyspnea,

          -  Moderate oxygen therapy: Oxygen flow &lt; 8 lpm (or FiO2 &lt; 0.60) to maintain a SpO2 &gt;or =
             92% (for long term oxygen therapy, the oxygen flow must be greater than baseline flow
             to maintain SpO2 &gt; or = 92%)

        Exclusion Criteria:

          -  Patient refusal

          -  COPD exacerbation with diagnosis highly related to pulmonary embolism, cardiac
             pulmonary edema, pneumothorax or sedative overdose

          -  No SpO2 signal

          -  Encephalopathy score &gt; 2

          -  Delirium

          -  Other respiratory support needed (intubation or NIV)

          -  Patient on withdrawal life support

          -  Advance neoplasia (palliative stage) or terminal respiratory distress

          -  Unavailability of FreeO2 device at the randomisation

          -  Non optimal patient collaboration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François Lellouche</last_name>
    <phone>4186568711</phone>
    <phone_ext>3572</phone_ext>
    <email>francois.lellouche@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre-Alexandre Bouchard</last_name>
    <phone>4186568711</phone>
    <phone_ext>2712</phone_ext>
    <email>pierre-alexandre.bouchard@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>François Lellouche</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

